<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04925752</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-528-9023</org_study_id>
    <nct_id>NCT04925752</nct_id>
  </id_info>
  <brief_title>Study to Assess the Effectiveness and Safety of Lenacapavir for Human Immunodeficiency Virus (HIV) Pre-Exposure Prophylaxis</brief_title>
  <acronym>PURPOSE 2</acronym>
  <official_title>A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People ≥ 16 Years of Age Who Have Sex With Partners Assigned Male at Birth and Are at Risk for HIV Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the efficacy of lenacapavir (LEN) in&#xD;
      preventing the risk of human immunodeficiency virus (HIV) infection relative to the&#xD;
      background HIV incidence rate.&#xD;
&#xD;
      The study will be conducted in 2 parts: a cross-sectional study (Incidence Phase) and a&#xD;
      double-blind, randomized study (Randomized Phase). The Incidence Phase will include initial&#xD;
      assessments that will provide an estimate of the concurrent background HIV incidence rate.&#xD;
      The Randomized Phase of the study will have a Blinded Phase, a LEN Open-label Extension (OLE)&#xD;
      Phase, and a pharmacokinetic (PK) Tail Coverage Phase.&#xD;
&#xD;
      The primary objective for the Incidence Phase of this study is to estimate the HIV background&#xD;
      incidence rate. The primary objective of the Randomized Phase of this study is to evaluate&#xD;
      the efficacy of lenacapavir for HIV pre-exposure prophylaxis (PrEP) in cisgender men (CGM),&#xD;
      transgender women (TGW), transgender men (TGM), and gender nonbinary people (GNB) ≥ 16 years&#xD;
      of age who have condomless receptive anal sex with partners assigned male at birth and are at&#xD;
      risk for HIV infection.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 28, 2021</start_date>
  <completion_date type="Anticipated">April 2027</completion_date>
  <primary_completion_date type="Anticipated">January 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence Phase: Background HIV Incidence Reported Per 100-Person-Years (PY)</measure>
    <time_frame>At Screening</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Randomized Phase: Background HIV Incidence Reported Per 100-PY of Follow-up</measure>
    <time_frame>When all participants have a minimum of 52 weeks of exposure to study drug or permanent discontinuation, whichever occurs first (maximum approximately 130 weeks)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>HIV Incidence Among Participants While Adherent to Study Drug</measure>
    <time_frame>When all participants have a minimum of 52 weeks of exposure to study drug or permanent discontinuation, whichever occurs first (maximum approximately 130 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Experiencing Treatment-Emergent Adverse Events</measure>
    <time_frame>When all participants have a minimum of 52 weeks of exposure to study drug or permanent discontinuation, whichever occurs first (maximum approximately 130 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Experiencing Clinically Significant Laboratory Abnormalities</measure>
    <time_frame>When all participants have a minimum of 52 weeks of exposure to study drug or permanent discontinuation, whichever occurs first (maximum approximately 130 weeks)</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Pre-Exposure Prophylaxis of HIV Infection</condition>
  <arm_group>
    <arm_group_label>Blinded Phase: LEN + Placebo-to-match (PTM) F/TDF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive the following for at least 52 weeks:&#xD;
Subcutaneous (SC) lenacapavir (LEN) 927 mg every 26 weeks&#xD;
Oral PTM Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) once daily&#xD;
Oral LEN 600 mg on Days 1 and 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Blinded Phase: Placebo LEN + F/TDF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive the following for at least 52 weeks:&#xD;
SC LEN placebo every 26 weeks&#xD;
Oral F/TDF 200/300 mg once daily&#xD;
PTM Oral LEN on Days 1 and 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LEN Open-Label Extension (OLE) Phase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After completion of the Blinded phase, participants will be offered entry into the LEN OLE Phase.&#xD;
Participants randomized to LEN will continue to receive SC LEN 927 mg every 26 weeks for a total of 2 doses.&#xD;
Participants randomized to F/TDF will receive SC LEN 927 mg on OLE Day 1, OLE Week 26, and OLE Week 52 and will also receive oral LEN 600 mg on OLE Days 1 and 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PK Tail Coverage Phase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>At the completion of the LEN OLE phase, participants will transition into the PK Tail Coverage phase.&#xD;
Additionally, participants that prematurely discontinue the study drug during blinded phase and participants that were randomized to LEN who choose not to continue in the LEN OLE Phase are also eligible to transition to the PK Tail Coverage Phase.&#xD;
Participants will receive oral F/TDF once daily for 78 weeks beginning 26 weeks after the last injection of LEN.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Lenacapavir (LEN)</intervention_name>
    <description>Tablets administered orally without regard to food</description>
    <arm_group_label>Blinded Phase: LEN + Placebo-to-match (PTM) F/TDF</arm_group_label>
    <arm_group_label>LEN Open-Label Extension (OLE) Phase</arm_group_label>
    <other_name>GS-6207</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>F/TDF</intervention_name>
    <description>Tablets administered orally</description>
    <arm_group_label>Blinded Phase: Placebo LEN + F/TDF</arm_group_label>
    <arm_group_label>PK Tail Coverage Phase</arm_group_label>
    <other_name>Truvada®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sub-cutaneous (SC) Lenacapavir (LEN)</intervention_name>
    <description>Administered via SC injections</description>
    <arm_group_label>Blinded Phase: LEN + Placebo-to-match (PTM) F/TDF</arm_group_label>
    <arm_group_label>LEN Open-Label Extension (OLE) Phase</arm_group_label>
    <other_name>GS-6207</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo SC LEN</intervention_name>
    <description>Administered via SC injections</description>
    <arm_group_label>Blinded Phase: Placebo LEN + F/TDF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PTM F/TDF</intervention_name>
    <description>Tablets administered orally</description>
    <arm_group_label>Blinded Phase: LEN + Placebo-to-match (PTM) F/TDF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PTM Oral LEN</intervention_name>
    <description>Tablets administered orally</description>
    <arm_group_label>Blinded Phase: Placebo LEN + F/TDF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
        Incidence Phase&#xD;
&#xD;
          -  CGM, TGW, TGM, and GNB who have condomless receptive anal sex with partners assigned&#xD;
             male at birth and are at risk for HIV infection.&#xD;
&#xD;
          -  HIV-1 status unknown at screening and no prior HIV-1 testing within the last 3 months&#xD;
&#xD;
          -  Sexually active with ≥ 1 partner assigned male at birth (condomless receptive anal&#xD;
             sex) in the last 12 months and 1 of the following:&#xD;
&#xD;
               -  Condomless receptive anal sex with ≥ 2 partners in the last 12 weeks&#xD;
&#xD;
               -  Documented history of syphilis, rectal gonorrhea, or rectal chlamydia in the last&#xD;
                  24 weeks&#xD;
&#xD;
               -  Self-reported use of stimulants with sex in the last 12 weeks&#xD;
&#xD;
        Randomized Phase&#xD;
&#xD;
          -  Negative local rapid fourth generation HIV-1 Ab/Ag test confirmed with central HIV-1&#xD;
             testing&#xD;
&#xD;
          -  Estimated glomerular filtration rate (eGFR) ≥ 60 mL/min at screening according to the&#xD;
             Cockcroft-Gault formula for creatinine clearance (CLcr)&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
        Incidence Phase&#xD;
&#xD;
          -  Prior use of long-acting systemic PrEP (including cabotegravir or islatravir trials)&#xD;
&#xD;
          -  Prior recipient of an HIV vaccine&#xD;
&#xD;
        Randomized Phase&#xD;
&#xD;
          -  Acute viral hepatitis A, B or C or evidence of chronic hepatitis B or C infection&#xD;
&#xD;
        Note: Other protocol defined Inclusion/Exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary</gender_description>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilead Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gilead Clinical Study Information Center</last_name>
    <phone>1-833-445-3230 (GILEAD-0)</phone>
    <email>GileadClinicalTrials@gilead.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mills Clinical Research</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90069</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UCSD Anti Viral Research Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Optimus Medical Group</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Washington Health Institute</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Therafirst Medical Center</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gary Richmond, MD, PA</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33316</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Midway Immunology &amp; Research Center, LLC</name>
      <address>
        <city>Fort Pierce</city>
        <state>Florida</state>
        <zip>34982</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Orlando Immunology Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Triple O Research Institute</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>RMR Core Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Be Well Medical Center</name>
      <address>
        <city>Berkley</city>
        <state>Michigan</state>
        <zip>48072</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>KC CARE Health Center</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Huntridge Family Clinic</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>South Jersey Infectious Disease</name>
      <address>
        <city>Somers Point</city>
        <state>New Jersey</state>
        <zip>08244</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cone Health/Regional Center for Infectious Disease Research Center</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Philadelphia FIGHT Community Health Centers, Jonathan Lax Treatment Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Central Texas Clinical Research</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Crofoot Research Center, INC</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77098</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 28, 2021</study_first_submitted>
  <study_first_submitted_qc>June 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2021</study_first_posted>
  <last_update_submitted>October 12, 2021</last_update_submitted>
  <last_update_submitted_qc>October 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

